Workflow
J&J(JNJ)
icon
Search documents
Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended
Benzinga· 2025-04-02 16:26
Core Viewpoint - Johnson & Johnson's shares experienced a significant drop of over 7.5% due to the announcement of a pending acquisition that is expected to dilute earnings, but the sell-off appears to have ended, and there is potential for a rally in the stock price [1]. Price Movement and Support Levels - The sell-off halted when shares reached the $153 level, which previously acted as a resistance point in November, indicating a common market behavior where resistance levels can turn into support [2]. - Investors who sold shares around the $153 mark may have second-guessed their decision after the price trend, leading to a psychological shift among traders [4][5]. Buyer Behavior and Market Dynamics - Former sellers who believed they made a mistake began to re-enter the market as buyers when the price fell back to $153, creating a support level at this price point [5]. - The presence of these buyers may lead to increased bidding activity, as concerns about being outbid could prompt them to raise their bid prices, potentially resulting in a bidding war that drives the stock price upward [6].
Why Johnson & Johnson Stock Is Sinking Today
The Motley Fool· 2025-04-01 18:38
There are tens of thousands of claimants and a majority would have needed to vote to accept the proposed settlement, which J&J claims it had. The judge said, however, that the "unreasonably short voting time" made the votes suspect and that at least half of the votes "cannot count." This marks the third time Johnson & Johnson's bankruptcy strategy has failed in court. Shares of Johnson & Johnson (JNJ -6.68%) are tumbling on Tuesday. The company's stock lost 6.3% as of 2:25 p.m. ET. The drop comes as the S&P ...
Johnson & Johnson shares fall as US judge rejects $10B talc settlement plan
Proactiveinvestors NA· 2025-04-01 15:24
About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...
Judge rejects Johnson & Johnson's $10B settlement to end baby powder lawsuits
New York Post· 2025-04-01 14:47
A US bankruptcy judge on Monday rejected Johnson & Johnson's $10 billion proposal to end tens of thousands of lawsuits alleging that its baby powder and other talc products cause ovarian cancer, marking the third time the company's bankruptcy strategy has failed in court. J&J has been attempting to resolve the lawsuits through a subsidiary company's bankruptcy, after two previous bankruptcy attempts failed in other courts. But the judge overseeing its case, US Bankruptcy Judge Christopher Lopez in Houston, ...
J&J's Third Bankruptcy Attempt to End Talc Suits Rejected
ZACKS· 2025-04-01 14:30
J&J faces more than 62,000 lawsuits for its talc-based products, primarily its baby powders. The lawsuits allege that its talc products contain asbestos, which caused many women to develop ovarian and some other cancers. J&J insists that talc-based products are safe and do not cause cancer. J&J has permanently discontinued the sale of its talc-based Johnson's Baby Powder globally. J&J's 3 Bankruptcy Filing in Texas After Two Failed Attempts In September, J&J, via a subsidiary called Red River Talc, filed fo ...
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer
ZACKS· 2025-03-31 14:42
Recent Developments Related to JNJ's Rybrevant J&J (JNJ) recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca's (AZN) Tagrisso in first-line EGFR-mutated non-small cell lung cancer ("NSCLC"). Data from the study suggests that the Rybrevant-Lazcluze combo significantly extends overall survival ("OS") in NSCLC patients with EGFR exon 19 deletions (ex19del) or exon 21 L858R substitution (L858R) mutations. At a median ...
Johnson & Johnson Needs Time To Consolidate (Technical Analysis And Downgrade)
Seeking Alpha· 2025-03-28 20:40
Core Insights - The article discusses a comparative analysis between AbbVie and Johnson & Johnson, suggesting that Benjamin Graham would favor Johnson & Johnson due to its consumer healthcare segment [1]. Group 1 - Johnson & Johnson stock (NYSE: JNJ) was the focus of a previous analysis published on February 19, 2025 [1]. - The analysis highlighted the strengths of Johnson & Johnson in the consumer healthcare market compared to AbbVie [1].
2 Recession-Proof Dividend Stocks to Buy and Hold
The Motley Fool· 2025-03-27 09:25
Core Viewpoint - Concerns about a potential recession are rising, and investors are advised to consider companies with strong fundamentals that can sustain dividends during economic downturns [1][2] Group 1: Companies with Strong Dividend Records - Companies like Medtronic and Johnson & Johnson are highlighted as strong candidates due to their long history of paying and increasing dividends, indicating robust fundamentals [2][11] - Medtronic has a record of 47 consecutive years of dividend increases, while Johnson & Johnson boasts 62 straight years, showcasing their resilience through various economic cycles [11] Group 2: Resilience During Economic Downturns - During recessions, consumer demand typically decreases, but defensive sectors like healthcare tend to perform better, as medical products and services are often essential [3][6] - Medtronic and Johnson & Johnson provide critical healthcare products that consumers are less likely to forgo, even in tough economic times [4][5] Group 3: Long-Term Growth Prospects - Both companies are positioned for long-term growth due to their leadership in the healthcare industry, which is expected to expand as the global population ages [7] - Medtronic's investments in robotic-assisted surgery and diabetes care, along with Johnson & Johnson's development of new medicines, are anticipated to drive future growth [8][9] Group 4: Market Position and Product Offerings - Medtronic's portfolio includes diabetes care, cardiovascular health, and other critical medical devices, while Johnson & Johnson has a diverse range of drugs and a strong medtech segment [4][5] - The introduction of innovative products, such as Medtronic's Hugo system and Johnson & Johnson's Ottava system for robotic surgery, represents significant growth opportunities [8]
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer
Prnewswire· 2025-03-26 15:45
Core Insights - Johnson & Johnson announced that RYBREVANT® (amivantamab-vmjw) in combination with LAZCLUZE™ (lazertinib) significantly improves overall survival (OS) compared to osimertinib in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations [1][2][3] Group 1: Study Results - The Phase 3 MARIPOSA study demonstrated that the median OS for RYBREVANT® plus LAZCLUZE™ has not yet been reached, while the median OS for osimertinib was 36.7 months [2][3] - At a median follow-up of 37.8 months, 56% of patients treated with RYBREVANT® and LAZCLUZE™ were alive at three and a half years compared to 44% for those on osimertinib [2] - Projections suggest that RYBREVANT® plus LAZCLUZE™ could extend median OS by at least 12 months compared to osimertinib [2] Group 2: Secondary Endpoints - The combination therapy also showed prolonged benefits in secondary endpoints, including intracranial progression-free survival (PFS) and time to symptomatic progression (TTSP), which was extended by more than 14 months compared to osimertinib [2][3] - The study met its primary endpoint in October 2023, indicating a statistically significant improvement in PFS compared to osimertinib [3] Group 3: Safety Profile - The safety profile of RYBREVANT® plus LAZCLUZE™ was consistent with previous analyses, with adverse event rates comparable to other RYBREVANT® regimens [2][3] - Most adverse events occurred early during treatment, and no new safety signals were identified with longer-term follow-up [2] Group 4: Regulatory Status - RYBREVANT® plus LAZCLUZE™ is approved in the U.S., Europe, and other markets for first-line treatment of patients with locally advanced or metastatic NSCLC with specific EGFR mutations [3][6] - The results from the MARIPOSA study will be shared with health authorities globally [3]
Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan
Newsfilter· 2025-03-25 17:11
Core Insights - Tevogen Bio has appointed David E. Banko as Global Head of Government Affairs and Patient Access, bringing over 30 years of experience in market access and health policy [1][2][3] - Mr. Banko will focus on advancing patient access to Tevogen's therapies, engaging with payers, and ensuring Health Technology Assessment readiness, which are critical for the company's commercialization strategies [2][4] - Tevogen Bio is a clinical-stage specialty immunotherapy company developing precision T cell therapies for infectious diseases and cancers, with a strong emphasis on patient accessibility and innovative business models [5][6][7] Company Strategy - The appointment of Mr. Banko is seen as a significant step towards commercialization readiness, emphasizing the need for defined value propositions for various stakeholders in the healthcare ecosystem [4] - Tevogen Bio aims to secure appropriate coding, coverage, and reimbursement for its therapies at launch, which is essential for market access [2][4] - The company has reported positive safety data from its proof-of-concept clinical trials and holds key intellectual property assets, including three granted patents and several pending patents related to artificial intelligence [6] Leadership and Expertise - Mr. Banko's previous roles include positions at Cordis Corp and B. Braun Medical Inc., where he successfully enhanced market access for innovative technologies [3] - Tevogen Bio's leadership team consists of experienced industry leaders and scientists focused on drug development and global product launch [7] - The company believes that accessible personalized therapeutics represent the next frontier of medicine, necessitating disruptive business models to sustain innovation [7]